Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON).

Trial Profile

Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON).

Discontinued
Phase of Trial: Phase III

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs Bardoxolone methyl (Primary)
  • Indications Renal failure; Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms BEACON
  • Sponsors Reata Pharmaceuticals
  • Most Recent Events

    • 14 Nov 2016 According to a Reata Pharmaceuticals Media Release, based on the data of an analysis assessing risk factors and its risk mitigation strategy for managing acute fluid retention of this trial, FDA approved the Phase 2 program in PAH (LARIAT)
    • 14 Nov 2016 Results published in the Reata Pharmaceuticals Media Release
    • 02 Jul 2014 According to a Kyowa Hakko Kirin media release, the results of this trial were were presented at the European Renal Association-European Dialysis and Transplant Association Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top